Urinary tract symptoms are a common complaint in patients with multiple sclerosis (MS) and comprise a great burden for this group of patients, affecting health-related quality of life. The quantification of such symptoms is not an easy task for both the clinician and patient and is mostly performed via the utilization of patient-reported outcome tools, such as questionnaires. Neurogenic Bladder Symptom Score (NBSS), originally developed by Welk et al,1 consists of 24 questions assessing the following domains: incontinence, storage, voiding, and consequences, while the last question covers an overall quality of life aspect. In order to apply these tools in daily clinical practice worldwide, cross-cultural adaptation is an essential step. In order to make a solid assumption regarding the validity of a translated questionnaire, the research team should follow strict methodological steps, as proposed by appropriate guidelines.2 We focused on a group of MS patients in Greece in order to produce a validated version of NBSS in the Greek language.